AbbVie | ABBV - Assets



AbbVie reported $136.17B in Assets for its fiscal quarter ending in March of 2025.


Assets Change Date
AbbVie USD 136.17B 1B Mar/2025
Abbott USD 84B 2.55B Jun/2025
ALKERMES USD 2.25B 170.83M Jun/2025
Amgen USD 87.9B 1.47B Jun/2025
AstraZeneca USD 112.42B 6.17B Jun/2025
Biogen USD 28.33B 297.1M Jun/2025
BioMarin Pharmaceutical USD 7.46B 309.33M Jun/2025
Bristol-Myers Squibb USD 94.68B 2.25B Jun/2025
Eisai JPY 1.41T 23.07B Jun/2025
Eli Lilly USD 100.92B 11.53B Jun/2025
Gilead Sciences USD 55.72B 713M Jun/2025
GlaxoSmithKline GBP 59.26B 1.45B Jun/2025
J&J USD 193.67B 13.57B Mar/2025
Medtronic USD 91.68B 1.71B Apr/2025
Merck USD 117.52B 2.4B Jun/2025
Neurocrine Biosciences USD 3.89B 202.1M Jun/2025
Novartis USD 104.4B 4.45B Jun/2025
Pacira USD 1.54B 49.41M Jun/2025
Perrigo USD 10.09B 334.3M Jun/2025
Pfizer USD 206.1B 1.93B Jun/2025
Regeneron Pharmaceuticals USD 38.22B 674M Jun/2025
Roche Holding CHF 101.8B 6.02B Dec/2024
Sanofi 124.96B 6.93B Jun/2025
UCB EUR 17.35B 1.72B Dec/2024
Ultragenyx Pharmaceutical USD 1.31B 5.66M Jun/2025
United Therapeutics USD 7.91B 164.1M Jun/2025
Vertex Pharmaceuticals USD 24.04B 1.16B Jun/2025
Zoetis USD 14.48B 381M Jun/2025